Genscript Biotech (HKSE:01548) Total Current Assets : HK$18,377 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Genscript Biotech Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genscript Biotech's total current assets for the quarter that ended in Dec. 2023 was HK$18,377 Mil.

Genscript Biotech Total Current Assets Historical Data

The historical data trend for Genscript Biotech's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Total Current Assets Chart

Genscript Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

4,324.05

7,707.40

12,783.03

13,740.84

18,377.33

Genscript Biotech Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Current Assets	Get a 7-Day Free Trial														12,783.03	11,754.96	13,740.84	19,334.60	18,377.33

Genscript Biotech Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genscript Biotech's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	15057.685	+	2137.199	+	416.622	+	765.82
	=	18,377

Genscript Biotech's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	15057.685	+	2137.199	+	416.622	+	765.82
	=	18,377

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Genscript Biotech (HKSE:01548) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genscript Biotech's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15057.685	-	10488.155	+	0.75 * 1648.625	+	0.5 * 416.622
=	6,014

Genscript Biotech Total Current Assets Related Terms

Thank you for viewing the detailed overview of Genscript Biotech's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genscript Biotech (HKSE:01548) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (HKSE:01548) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

GNNSF:USA G51:Germany

Address

No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100

Website

https://www.genscript.com

GenScript Biotech is a China-based provider of life science research services and products. Founded in 2002, it is best known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, it owns 57.1% of Nasdaq-listed Legend Biotech, whose key pipeline asset is a BCMA-targeting CAR-T treatment for multiple myeloma. We estimate that more than two thirds of GenScript's valuation is from its ownership stake in Legend.

Executives

Wang Luquan	2401 A concert party to an agreement to buy shares
Wang Ye	2101 Beneficial owner
Zhang Fangliang	2401 A concert party to an agreement to buy shares
Huang Lili	2202 Interest of your spouse
Hu Zhiyong	2201 Interest of corporation controlled by you
Jin Weihong	2201 Interest of corporation controlled by you
Genscript Corporation	2101 Beneficial owner
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Hillhouse Investment Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Investment Management, Ltd.	2102 Investment manager
Gns Holdings Limited	2101 Beneficial owner
Hillhouse Capital Management V, Ltd.	2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd.	2102 Investment manager

Genscript Biotech (HKSE:01548) Headlines

No Headlines